IMCRImmunocore Holdings plc

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M+26.2% YoY

Gross Profit

$74M97.7% margin

Operating Income

-$16M-21.2% margin

Net Income

-$12M-15.4% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+6.9%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$23M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$664M

Stockholders' Equity

$359M

Cash & Equivalents

$505M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$60M	+26.2%
Gross Profit	$74M	$59M	+24.0%
Operating Income	-$16M	-$14M	-16.4%
Net Income	-$12M	-$17M	+31.7%

Revenue Segments

Collaboration Revenue

$53,000100%

Geographic Segments

UNITED STATES

$56M74%

Europe

$15M20%

Rest of World

$4M6%

IMCR Q2 2024 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena